health.10ztalk.com
Another Rituximab Biosimilar Passes Lymphoma Test ⋆ health.10ztalk.com
SAN DIEGO — A rituximab biosimilar demonstrated noninferiority to European (EU)-licensed rituximab (MabThera) in a randomized trial involving patients with low-tumor burden follicular lymphoma. The biosimilar PF-05280586 from Pfizer led to an objective response rate of 75.5% at 26 weeks as compared with 70.7% for patients treated with rituximab-EU. The estimated 1-year progression-free survival (PFS) …